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TherapyAlzheimer's disease (AD) is the most common type of dementia in the elderly. It is characterized by the deposi-
tion of two forms of aggregateswithin the brain, the amyloidβ plaques and tau neuroﬁbrillary tangles. Currently,
no disease-modifying agent is approved for the treatment of AD. Approved pharmacotherapies target the periph-
eral symptoms but they do not prevent or slow down the progression of the disease. Although several
disease-modifying immunotherapeutic agents are in clinical development, many have failed due to the lack of
efﬁcacy or serious adverse events. Epigenetic changes including DNA methylation and histone modiﬁcations
are involved in learning andmemory and have been recently highlighted for holding promise as potential targets
for AD therapeutics. Dynamic and latent epigenetic alterations are incorporated inADpathological pathways and
present valuable reversible targets for AD and other neurological disorders. The approval of epigenetic drugs for
cancer treatment has opened the door for the development of epigenetic drugs for other disorders including neu-
rodegenerative diseases. In particular, methyl donors and histone deacetylase inhibitors are being investigated
for possible therapeutic effects to rescue memory and cognitive decline found in such disorders. This review ex-
plores the area of epigenetics for potential AD interventions and presents the most recent ﬁndings in this ﬁeld.
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61. Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative dis-
order, with over 35 million cases worldwide (Selkoe, 2012). The four
acetylcholinesterase inhibitors, donepezil, rivastigmine, galantamine
and tacrine, along with the NMDA receptor antagonist memantine
are the only FDA-approved drugs for AD; however, they merely target; APP, amyloid β precursor pro-
g protein; CREB, cAMP response
, DNA methyltransferase; FAD,
e deacetylase; LOAD, late onset
brillary tangles; PS, presenilin;
y protein 1.
igenetics Laboratory, College of
oad, Kingston, RI 02881, USA.
rights reserved.the symptoms and do not prevent the progressive loss of memory,
cognitive and executive functions in AD patients. With the increase
in life expectancy and the absence of disease-modifying agents, the
number of people with AD is expected to triple within the upcoming
40 years (Barnes & Yaffe, 2011; Huang & Mucke, 2012; Tricco et al.,
2012). The annual costs for AD and other dementias in the US in
2013 are estimated to be over $200 billion and are expected to reach
$1.2 trillion in 2050 (Alzheimer's Association, 2013). With such a
heavy socioeconomic burden, there is an urgent need to ﬁnd novel
and improved treatments for AD. Throughout the last century, the ad-
vances acquired in health related ﬁelds were able to increase the
lifespan of AD patients, yet this needs to be matched with discoveries
that improve the quality of life of people with this debilitating disor-
der. New targets should be identiﬁed and investigated for possible
AD therapeutics that tackle its core pathophysiology aswell as prevent
the decline in memory and cognitive functions associated with the
disease.
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tive and executive functions, with two types of pathological deposits
found in the brain, the extracellular amyloid β (Aβ) plaques and the in-
tracellular tau neuroﬁbrillary tangles (NFTs). Senile plaques are mainly
composed of Aβ which is cleaved off the larger amyloid β precursor
protein (APP) by β-site APP cleaving enzyme (BACE), also known as
β-secretase, and γ-secretase (Shoji et al., 1992; Citron et al., 1995).
According to the amyloid hypothesis, Aβ and its aggregates are respon-
sible for the neurodegeneration and dementia in AD through mecha-
nisms that involve disturbances in calcium homeostasis which make
cells more vulnerable to toxicants that can cause further damage and
NFTs (Hardy & Higgins, 1992; Mattson et al., 1992; Selkoe, 1993). The
hypothesis was supported by the fact that mutations on APP are
connected to hereditary types of AD (Hardy & Higgins, 1992). Early
onset familial AD (FAD) could also be due to mutations on genes
encoding the presenilin (PS) membrane proteins PS1 and PS2 (Tanzi
et al., 1996; Czech et al., 2000). PS mutations increase the production
of themore aggregative 42 amino acid-long Aβ (Aβ42) fromAPP and el-
evated Aβ42 levels were observed in the blood and brains of FAD pa-
tients with PS abnormalities (Czech et al., 2000). In addition, neurons
lacking the PS1 gene fail to produce Aβ peptides (De Strooper et al.,
1998; Naruse et al., 1998). PS1 was found to be related to the enzyme
γ-secretase (De Strooper et al., 1998; Shimojo et al., 2007). These ﬁnd-
ings suggest that Aβ and its aggregates are involved in the pathology of
AD as proposed in the amyloid hypothesis.
NFTs are composed of tau protein which belongs to a family of
microtubule-associated proteins that normally promote microtubule
assembly (Weingarten et al., 1975). When hyperphosphorylated,
tau loses its normal function and becomes prone to form pathological
aggregates causing disorders known as tauopathies of which AD is the
most common (Alonso et al., 1997; Lee et al., 2001). Both Aβ and tau
have been associated with neurodegeneration and memory decline
and have been extensively targeted for AD interventions such as im-
munotherapeutics, enzyme modulators, and aggregation inhibitors
(Hardy & Higgins, 1992; Selkoe, 1993; Hutton et al., 1998; Lee et al.,
2001; Hardy & Selkoe, 2002; Iqbal et al., 2009).
Epigenetics deals with acquired and heritable modiﬁcations on
DNA that regulate the expression and functions of genes without af-
fecting the DNA nucleotide sequence. These include DNAmethylation
and hydroxymethylation, histone modiﬁcations and non-coding RNA
regulation. Histone modiﬁcations consist of acetylation, methylation,
crotonylation, ubiquitination, sumoylation, phosphorylation, hydrox-
ylation and proline isomerization (Davie & Spencer, 1999; Peterson &
Laniel, 2004; Kouzarides, 2007; Houston et al., 2013). All these path-
ways act as mediators between the environment and the genome,
these epigenetic changes are activated by various conditions such as
stress or exposure to environmental toxicants and in turn they result
in a variety of responses including gene transcription or silencing.
Epigenetic changes are dynamic and unlike genetic mutations, they
can be reversed for therapeutic purposes by targeting enzymes or
other factors that control or maintain them (Henikoff & Matzke, 1997;
Feinberg, 2008; Liu et al., 2008; Mill, 2011; Caraci et al., 2012). As
changes within the genetic makeup itself are limited and the environ-
ment cannot freely amend the DNA sequence, epigenetics is the mech-
anism through which the environment can affect gene expression and
function which can be employed as a medical intervention for diseases
where epigenetics play a pathological role (Jaenisch & Bird, 2003; Mill,
2011). Furthermore, some age related changes are also mediated
through epigenetics (Feinberg, 2008).
The majority of AD cases are sporadic or late onset AD (LOAD). Only
about 5% of cases are familial or early onset ADwhich is associatedwith
rare mutations on the APP, PS1 and PS2 genes (Goate et al., 1991;
Sherrington et al., 1995; Tanzi, 2012). The sporadic nature of AD sug-
gests that epigenetics plays an important role in the pathology of the
disease; a hypothesis that is supported by recent ﬁndings from our lab-
oratory and others (Zawia & Basha, 2005; Lahiri et al., 2008;Wang et al.,2008a;Wu et al., 2008b; Lahiri et al., 2009; Zawia et al., 2009;Mastroeni
et al., 2011; Mill, 2011). This review explores epigenetic mechanisms as
possible targets for AD therapeutics and highlights the current status of
epigenetics in AD pathology and drug discovery.
1.1. Epigenetics of the brain and memory formation
Epigenetic dynamics within cells play a major role in their differ-
entiation and in determining their functional type as hepatocytes in
the liver, neurons in the brain, skin cells, or other cells, as well as
becoming cancerous or not (Feinberg, 2008; Chadwick, 2012). Epige-
netics is involved in various brain related disorders and physiologic
responses that genetics alone does not completely explain including
AD, depression, schizophrenia, glioma, addiction, Rett syndrome, al-
cohol dependence, autism, epilepsy, multiple sclerosis and stress
(Shahbazian & Zoghbi, 2002; Jaenisch & Bird, 2003; Zawia et al.,
2009; Nguyen et al., 2010; Qureshi & Mehler, 2010; Maze & Nestler,
2011; Mifsud et al., 2011; Taqi et al., 2011; Heim & Binder, 2012;
Kreth et al., in press; Maric & Svrakic, 2012; Orr et al., 2012; Inkster
et al., 2013). As neurons do not divide and cannot be replaced after
degeneration, epigenetic changes resulting in neuronal dysfunction
need to be targeted and modiﬁed to prevent neurodegeneration (Bird,
2007; Selvi et al., 2010).
Recent studies have pointed out the importance of epigenetics in
brain development and functions including learning and memory
(Feng et al., 2007; Miller & Sweatt, 2007; Molfese, 2011; Sultan &
Day, 2011). In particular, DNA methylation and histone acetylation
both play an important role in memory formation (Levenson et al.,
2006; Miller et al., 2008). Other histone modiﬁcations involved in
memory are methylation and phosphorylation (Chwang et al., 2006;
Gupta et al., 2010; Molfese, 2011).
DNA methylation is catalyzed by DNA methyltransferases (DNMTs)
in the presence of themethyl donor S-adenosylmethionine (SAM) (Yen
et al., 1992). The DNMT family of enzymes includes DNMT1, DNMT2,
DNMT3a, and DNMT3b (Okano et al., 1999). It is found that DNMT3a
and DNMT3b are responsible for de novo methylation and establish
DNA methylation patterns while DNMT1 has preference for hemi-
methylated DNA (Hsieh, 1999; Okano et al., 1999; Chen et al., 2003).
DNA methylation occurs on the 5′ position of cytosine in CpG rich re-
gions (Bird, 1986). This epigeneticmechanism regulates gene transcrip-
tion and plays a particular role in memory functions (Liu et al., 2009;
Day & Sweatt, 2010; Korzus, 2010). Memory and learning abilities de-
cline with age which correlates with an overall reduction in DNAmeth-
ylation (Liu et al., 2009). Furthermore, methylation on certain locations
of the APP promoter in the human cortex is reduced with age (Tohgi et
al., 1999).
DNMTs are considered crucial for memory functions (Miller &
Sweatt, 2007). DNMTs regulate methylation within the promoter of
reelin, an extracellular glycoprotein that is involved in memory forma-
tion in the adult brain (Weeber et al., 2002; Levenson et al., 2006). Pro-
tein levels of DNMT1 and DNMT3a are reduced in the cortex of aged
monkeys compared to early time points (Bihaqi et al., 2011). Moreover,
conditional knockout mice lacking the expression of Dnmt1 and Dnmt3a
genes in forebrain neurons perform worse on the Morris water maze
hippocampus relatedmemory task than wild-type littermates or knock-
out mice lacking the expression of only one of the genes (Feng et al.,
2010). The gene expression of Dnmt3a2 decreases with age in mouse
cortex and hippocampus (Oliveira et al., 2012). This age-related decline
in Dnmt3a2 gene expression is linked to memory decline that can be re-
covered by restoring DNMT3a2 levels (Oliveira et al., 2012).
Hydroxylation of 5-methylcytosine to 5-hydroxymethylcytosine by
ten-eleven translocation (TET) enzymes is an important regulatory path-
way involved in brain development, aging and disease (Szulwach et al.,
2011). Levels of 5-hydroxymethylcytosine are signiﬁcantly higher in neu-
rons than in cells of other tissues (Globisch et al., 2010; Szulwach et al.,
2011). DNA hydroxymethylation, levels of 5-hydroxymethylcytosine
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also been reported with aging in mouse hippocampus (Chouliaras et al.,
2011, 2012a, 2012b). Such epigenetic changes could be prevented by
50% caloric restriction diet throughout the mice lifetime after weaning
(Chouliaras et al., 2011, 2012a, 2012b).
Moreover, mutations on methyl CpG binding protein 2 (MeCP2)
may contribute to the development of Rett syndrome; a life-longneuro-
developmental disorder with marked learning disabilities (Amir et al.,
1999). Other neurological abnormalities such as autism and infantile
encephalopathy have been associated with disturbances in MeCP2
(Moretti & Zoghbi, 2006; Chahrour et al., 2008). MeCP2 binds to meth-
ylated cytosine in CpG dinucleotides and inhibits or promotes gene ex-
pression by recruiting transcription repressors or activators like cAMP
response element-binding protein 1 (CREB1) (Jones et al., 1998; Nan
et al., 1998; Chahrour et al., 2008). This also involves MeCP2 binding
to histone deacetylase complex (Jones et al., 1998; Nan et al., 1998).
MeCP2 levels are found to decrease with age in primates (Bihaqi et al.,
2011).
Histone acetylation is also involved in the regulation of learning and
memory (Levenson et al., 2004; Martin & Sun, 2004). The most widely
studied histone modiﬁcation is regulated by two groups of enzymes,
histone acetyltransferases (HATs) and histone deacetylases (HDACs).
The HDAC family of enzymes has been studied extensively for implica-
tions in cancer. Aberrant overexpression of various HDACs has been
reported in different cancer types including gastric, pancreatic, breast,
lung and colon cancer (Johnstone, 2002; Barneda-Zahonero & Parra,
2012; New et al., 2012). Many HDAC inhibitors are in clinical trials for
cancer therapy, vorinostat and romidepsin have been approved by the
FDA for cutaneous T-cell lymphoma (Mann et al., 2007; Kim et al.,
2012; Nebbioso et al., 2012). There are 18 HDACs identiﬁed that belong
to four classes I, II, III and IV according to their sequence homology (Xu
et al., 2007). Class I HDAC2, class IIb HDAC6 and class III sirtuins (SIRTs)
1 and 2 are linked to AD pathology (de Oliveira et al., 2012; Karagiannis
& Ververis, 2012). Acetylation of histone H3 in the hippocampus ac-
companies long-term memory formation in rats as determined in hip-
pocampal tissues collected 1 h after fear conditioning experiments
(Levenson et al., 2004). Increasing histone acetylation by the adminis-
tration of theHDAC inhibitor sodiumbutyrate to rats prior to contextual
fear conditioning improves memory formation (Levenson et al., 2004).
Class I HDAC inhibitors sodiumbutyrate, sodiumvalproate and vorinostat
enhance cognition in APP/PS1 double transgenic AD mouse model as
evaluated by contextual fear conditioning tests (Kilgore et al., 2010).
Overexpression of HDAC2 and not HDAC1, both Class I HDACs, in mice
impairs memory and the chronic administration of the HDAC inhibitors
vorinostat or sodium butyrate enhances cognition (Guan et al., 2009).
HDAC2 knockout mice display improved memory in fear conditioning
experiments over wild-type mice (Guan et al., 2009). Consequently,
downregulation or inhibition of HDACs 2 and 6 constitutes important
therapeutic targets for memory related disorders.
1.2. Epigenetic changes in AD
1.2.1. Histone modiﬁcations in AD
Increased levels of HDAC2 have been associated with cognitive im-
pairment in CK-p25 AD mouse model which seems to be mediated
through glucocorticoid receptor induced HDAC2 transcription (Graff et
al., 2012). Postmortem studies reported that HDAC2 and not HDAC1 or
HDAC3 is increased within the hippocampus of AD patients (Graff et
al., 2012). Class II HDAC6 levels are elevated in AD cortex andhippocam-
pus by 52% and 91% respectively (Ding et al., 2008). Tau co-localizes
with HDAC6 in AD hippocampus and in vitro, and downregulation of
HDAC6 decreases tau phosphorylation at Thr231 (Ding et al., 2008).
Hyperphosphorylation of tau inhibits its normal functions and promotes
its aggregation (Alonso et al., 1997). In particular tau phosphorylation
at Thr231 restrains its normal function of binding to microtubules
(Sengupta et al., 1998). Class III HDACs or sirtuins are a family ofenzymes that includes seven members named SIRT1-7 (Gray &
Ekstrom, 2001). In addition to histones, SIRTs are responsible for
deacetylation of other molecules like some proteins involved in AD pa-
thology. For example SIRT1 accounts for tau deacetylation which is con-
sidered neuroprotective while tau acetylation contributes to tau
dysfunction and aggregation (Min et al., 2010; Cohen et al., 2011;
Stunkel & Campbell, 2011). SIRT1 is lower in the AD cortexwhich corre-
lates with the presence of tau pathology and memory impairment
(Julien et al., 2009). There is evidence that SIRT1 also stimulates
α-secretase which cleaves APP within the Aβ sequence and protects
against Aβ accumulation (Donmez et al., 2010; Wang et al., 2010;
Raghavan & Shah, 2012). SIRT1 is themost studied sirtuin, other sirtuins
are also expressed in the brain and SIRT2 has been presented as a drug
target for neurodegenerative diseases such as Parkinson's and
Huntington's diseases (de Oliveira et al., 2012).
1.2.2. DNA methylation in AD
DNA methylation and factors such as DNMT1 are signiﬁcantly
reduced in neurons of entorhinal cortex layer II in AD patients
(Mastroeni et al., 2010). Reductions in methylation are particularly lo-
calized in tangles containing neurons (Mastroeni et al., 2010). Other
studies have demonstrated that there is abnormal methylation in AD
patients (Wang et al., 2008a; Bakulski et al., 2012). When studying
DNAmethylation within the cerebral cortex of AD and control subjects,
two out of the ﬁfty loci examined were differentially methylated in AD
which represent an acceleration of aging-linked alterations (Siegmund
et al., 2007). In an AD discordant pair of monozygotic twins, extensive
plaques and NFTs were present and less methylation was found in the
cortex of the AD twin compared to the non-AD twin (Mastroeni et al.,
2009). However, some studies found no differences in the methylation
patterns of AD related genes (Barrachina& Ferrer, 2009). The difﬁculties
in obtaining postmortem AD brain tissues for such studies and the var-
iability among the available tissues aswell as the different end points of
methylation analyzed within these studies account for their various
ﬁndings.
The promoter region within the APP gene is GC rich suggesting
that it can be modulated through methylation (Pollwein et al., 1992).
APP promoter displays differential methylation within the human
brain (Rogaev et al., 1994). Hypomethylation of the APP promoter
was reported to correlate with APP overexpression in AD (West et al.,
1995). DNA methylation controls BACE and PS1 expression and conse-
quently Aβ levels (Fuso et al., 2005). PS1 expression and methylation
are altered in LOAD (Wang et al., 2008a). However, the changes on
PS1 gene methylation in AD brains were not signiﬁcant (Wang et al.,
2008a). Another study did not detect signiﬁcant changes in PS1, APP
and tau genes methylation in the cortex and hippocampus of AD pa-
tients compared to controls (Barrachina & Ferrer, 2009). Lower paternal
age was signiﬁcantly associated with the increase in LOAD risk which
might involve DNA methylation (Farrer et al., 1991). The challenges in
acquiring and handling human brain tissues make it difﬁcult to have a
large number of matched controls and AD samples, however the avail-
able studies along with the sporadic and non-Mendelian inheritance
nature of the disease suggest that epigenetics is indeed involved in
AD. Further research is needed to examine the epigenetic changes af-
fecting AD biomarkers including APP, tau, BACE, PS1 and PS2 among
others, as well as global gene methylation patterns which would help
with the early diagnosis of the disease.
1.2.3. Non-coding RNA in AD
Non-coding RNA can inﬂuence gene expression via epigenetic
mechanisms affecting DNA methylation, histone modiﬁcations and
chromatin remodeling (Costa, 2008). Various microRNAs are differen-
tially expressed in AD and alter the expression of AD pathological inter-
mediates (Cogswell et al., 2008; Nunez-Iglesias et al., 2010; Provost,
2010). An example is microRNA-101 which negatively regulates APP
levels and is reduced within the brain cortex of AD patients (Hebert et
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is lowered early in AD and regulates BACE1 expression (Wang et al.,
2008b). BACE1-AS is a long non-coding RNA antisense transcript of
BACE1 that improves BACE1 stability and expression and is upregulated
in the hippocampus and cortex of AD patients (Faghihi et al., 2008). Ad-
ditional changes on non-coding RNAs are reported in AD and have been
reviewed recently (Schonrock & Gotz, 2012). However, due to the cur-
rent limitations and the absence of methods that can target or modify
non-coding RNAs for therapeutic purposes, only few are mentioned
within this review.
2. Epigenetic therapeutic approaches for AD
2.1. HDAC inhibitors
HDAC inhibitors show promise for cognitive improvement and are
being considered for drug development for AD (Fischer et al., 2007;
Abel & Zukin, 2008; Guan et al., 2009). Epigenetic changes play a role
in cognitive decline and reversing such changes by inhibiting HDAC2
improves memory and cognitive functions (Graff et al., 2012). Treat-
ment of hippocampal neurons with Aβ promotes HDAC2 transcription
suggesting that the traditional target of Aβ lowering in AD should be
complemented with the reversal of epigenetic changes that were
caused by increased Aβ levels (Graff et al., 2012). This might explain
why Aβ lowering is not always successful in improving memory and
cognitive deﬁcits when subsequent epigenetic changes are not reversed
as well (Graff et al., 2012). Crebinostat, an HDAC inhibitor, improves
memory in mice (Fass et al., 2013). Administration of any of the three
Class I HDAC inhibitors sodium valproate, sodium butyrate and
vorinostat, which is an HDAC inhibitor approved by the FDA for cancer,
improves memory in the APPswe/PS1dE9 AD mouse model (Kilgore et
al., 2010). Hence, HDAC inhibitors could be promising therapeutic
agents for AD and other disorders associated with dementia and cogni-
tive impairments.
Valproic acid, which is used as an anticonvulsant in epileptic pa-
tients and as a mood stabilizer in bipolar disorder patients (Phiel et
al., 2001), is a known HDAC inhibitor and has therefore been proposed
for use in cancer and AD (Gottlicher et al., 2001; Kramer et al., 2003;
Nalivaeva et al., 2009). In addition, valproate seems to have multi-
target effects that can be useful for AD including the inhibition of the en-
zyme responsible for tau phosphorylation glycogen synthase kinase 3
beta (GSK3β) (Loy & Tariot, 2002). Valproic acid lowers Aβ in the
PDAPP transgenic mouse model of AD (Su et al., 2004). However, in a
2-year clinical trial, valproate did not improve cognitive function or
slow memory decline in moderate AD patients and was associated
with adverse effects such as somnolence, tremor, weakness and dys-
pnea (Fleisher et al., 2011; Tariot et al., 2011).
Another HDAC inhibitor, sodium phenylbutyrate was found to im-
prove memory and lower tau phosphorylation by GSK3β in APPswe
transgenic AD mice (Ricobaraza et al., 2009). EVP-0334 is an HDAC in-
hibitor developed for AD by EnVivo Pharmaceuticals that successfully
completedphase I clinical trials andwas deemed safe for further testing,
however, detailed information on the trial have not been made avail-
able yet (Mack, 2010; Arrowsmith et al., 2012; Caraci et al., 2012). A
class II HDAC inhibitor referred to asW2 lowers Aβ, tau phosphorylated
at Thr181 and improves cognition in hAPP transgenic mice (Sung et al.,
2013). The authors also found thatW2 and I2, a class I and II HDAC inhi-
bitor, both downregulated genes involved in Aβ production and pro-
moted genes responsible for Aβ degradation in vitro (Sung et al., 2013).
2.2. Sirtuins
Class III HDACs or SIRTs are epigenetic targets for cancer and AD
(Outeiro et al., 2008; Albani et al., 2010; Huber & Superti-Furga,
2011). The natural product found in red grape skin andwine resveratrol
is a SIRT1 activator that improves cognition in mice (Kim et al., 2007).However, resveratrol cognitive beneﬁts involve other mechanisms be-
sides SIRT1 activation and its epigenetic functions (Kim et al., 2007;
Huber & Superti-Furga, 2011). A phase II study is currently recruiting
mild to moderate AD patients to study the effects of resveratrol on AD
biomarkers including cerebrospinal ﬂuid (CSF) tau and Aβ levels as
well as memory and daily performance using tests like Mini-Mental
State Examination (MMSE) and Alzheimer's Disease Assessment Scale-
Cognitive (ADAS-Cog) (ClinicalTrials.gov., identiﬁer: NCT01504854,
2013). Two SIRT activators developed by GSKwere in phase I clinical tri-
als, SRT2104 and SRT2379, recently the results from one of the trials
were published and showed that SRT2104 was well tolerated by
human subjects and suitable for further clinical trials (Townsend,
2011; Hoffmann et al., 2013). Interestingly, the nonselective SIRT inhib-
itor nicotinamide lowers phosphorylated tau and improves cognition in
micedemonstrating that SIRTmodulation involves complexmechanisms
(Green et al., 2008; Stunkel & Campbell, 2011). Nicotinamide is in phase
II clinical trial for AD (ClinicalTrials.gov., identiﬁer: NCT00580931, 2012).
Furthermore, the administration of the SIRT2 inhibitor AK1 directly into
the hippocampus protects against neurodegeneration in tau transgenic
mice without altering tau tangles (Spires-Jones et al., 2012).
2.3. HATs
Less attention has been given to HAT enzymes as epigenetic targets
for AD. Three HATs are involved inmemory formation CREB binding pro-
tein (CBP), p300 and p300/CBP associated factor (PCAF) which might
represent more speciﬁc targets than HDACs (Korzus et al., 2004; Selvi et
al., 2010). CBP plays an important role in memory as CBP deﬁcient mice
display impaired long-term memory formation (Oike et al., 1999;
Wood et al., 2005). In humans, mutations on the CBP gene result in
Rubinstein–Taybi syndrome which is characterized by mental retarda-
tion (Rubinstein & Taybi, 1963; Petrij et al., 1995). Inducing the
expression of CBP within the brains of 3×Tg-AD triple transgenic AD
mouse model recovers the impaired memory functions in these mice
(Caccamo et al., 2010). On the other hand, inhibition of the HAT p300
by using the commercially available p300 inhibitor C646 reduces the
levels of acetylated tau and phosphorylated tau at Ser202 in vitro (Min
et al., 2010). The natural plant product curcumin possesses p300/CBP
HAT inhibitor activity and is in phase II clinical trial to study its cognitive
effects andAβ lowering potential in ADpatients (Balasubramanyamet al.,
2004; Marcu et al., 2006; ClinicalTrials.gov., identiﬁer: NCT01383161,
2012). Previous trials with a smaller number of AD subjects reported no
signiﬁcant changes between curcumin- and placebo-treated groups
(Hamaguchi et al., 2010; Ringman et al., 2012). While in transgenic
animal models, curcumin decreased oxidative damage and Aβ
pathology by affecting anti-inﬂammatory pathways (Lim et al., 2001;
Yang et al., 2005; Begum et al., 2008; Hamaguchi et al., 2010).
2.4. DNA methylation
There are multiple ways for targeting DNA methylation for
therapeutic purposes (Klose & Bird, 2006). DNA methylation affects
the expression of the AD related intermediates APP, PS1 and Aβ
(Fuso et al., 2005). It has been hypothesized that hypomethylation
of the promoter regions of such genes like PS1 leads to the
overexpression of their products including Aβ (Mulder et al., 2005).
Overexpression of DNMT3a2 within the hippocampus of old mice
increases overall methylation and improves memory (Oliveira et al.,
2012).
The levels of the methyl donor SAM are lower in the CSF and within
the brains of AD patients (Bottiglieri et al., 1990; Bottiglieri et al., 1994;
Morrison et al., 1996). However, in another study, there was no differ-
ence in SAM–CSF levels in AD patients vs. healthy subjects (Mulder et
al., 2005). Nevertheless, treatment with SAM reduces BACE1, PS1 and
Aβ production in vitro in human neuroblastoma cells (Scarpa et al.,
2003; Fuso et al., 2005). Moreover, the administration of SAM adjunct
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symptoms and ability to remember as determined by cognitive and
physical symptoms questionnaire (CPFQ) (Levkovitz et al., 2012).
Betaine, the methyl donor used conventionally for homocystinuria
treatment (Key, 2000), was tested in 8 AD patients for 24 weeks and
failed to demonstrate cognitive improvement (Craig, 2004; Knopman
& Patterson, 2001). However, the small number of patients and the
lack of a placebo-treated control group suggest that further trials
are needed to properly evaluate betaine's efﬁcacy in AD (Knopman
& Patterson, 2001), especially that elevated homocysteine has been
associated with dementia and AD and betaine lowers homocysteine
(Seshadri et al., 2002). In a more recent study in mice, betaine was
able to improve memory that was compromised by prior lipopolysac-
charide administration (Miwa et al., 2011).
2.5. Non-coding RNA
Several non-coding RNAs are involved in AD pathology and could
present speciﬁc diagnostic and therapeutic targets for the disease
(Costa, 2008; Provost, 2010). These include BACE1-AS, microRNA-34c,
microRNA-101, and microRNA-107 (Cogswell et al., 2008; Faghihi et
al., 2008; Wang et al., 2008b; Vilardo et al., 2010; Zovoilis et al., 2011).
However, concerns about ways to alter such targets, off target effects,
and delivery methods still need to be adequately addressed before
having epigenetic treatments capable of affecting non-coding RNAs.
Targeting non-coding RNA regions on APP by the antibiotic erythromy-
cin, the antidepressant paroxetine andN-acetyl cysteine has been found
to reduce Aβ in TgCRND8 transgenicmice (Tucker et al., 2005; Tucker et
al., 2006).
2.6. Beyond epigenetics: epigenetics and transcription
Epigenetics is an important mediator that inﬂuences DNA tran-
scription and translation. The aim of AD therapy is to enhance the tran-
scription of genes involved in memory formation and reduce the
transcription of pathogenic intermediates in the disease process like
tau, APP, and BACE1. Hence, transcription factors constitute valid tar-
gets for developing novel treatments for AD. One of the important tran-
scription factors for learning and memory is CREB (Silva et al., 1998).
CREB is an essential mediator of memory improvement following
HDAC inhibition as CREB has histone acetylation activity through re-
cruitment of the histone acetyltransferase CBP (Vecsey et al., 2007).
HDAC inhibitors, such as phenylbutyrate or crebinostat promote the
transcription of genes involved in memory functions as seen with
crebinostat which upregulates the CREB target gene early growth re-
sponse 1 (egr1), which is involved in memory formation (Ricobaraza et
al., 2009; Fass et al., 2013). A clinical trial studying the effects of the
antiplatelet drug cilostazol on cognition in AD patients co-administered
with donepezil is currently in progress (ClinicalTrials.gov., identiﬁer:
NCT01409564, 2011). The rationale behind choosing cilostazol is to pro-
mote the phosphorylation of CREB which regulates its activity and con-
sequential expression of genes that are controlled by CREB (Bito et al.,
1996; Silva et al., 1998; ClinicalTrials.gov., identiﬁer: NCT01409564,
2011). Cilostazol protects against Aβ triggered cognitive impairment
in mice and improves memory following cerebral hypoperfusion dam-
age in rats (Watanabe et al., 2006; Hiramatsu et al., 2010).
An important transcription factor involved in AD is speciﬁcity protein
1 (Sp1). It binds to GC-rich regions within the promoters of APP, tau and
BACE1 and upregulates their expression (Pollwein et al., 1992; Hoffman
& Chernak, 1995; Docagne et al., 2004). Sp1 is able to bind to CpG sites
in gene promoters that have such speciﬁc binding motifs and activate
their transcription whether they are methylated or non-methylated
(Holler et al., 1988). Furthermore, Sp1 can trigger epigenetic modiﬁca-
tions as it regulates the expression of DNMT1 (Kishikawa et al., 2002).
Tolfenamic acid promotes Sp1 protein degradation and lowers APP,
tau, and BACE1 expression as well as Aβ levels and improves cognitionin mice (Abdelrahim et al., 2006; Adwan et al., 2011; Adwan et al.,
unpublished observation; Subaiea et al., in press). Tolfenamic acid is
scheduled to be tested in AD patients in the near future.
3. Discussion and conclusions
Epigenetic changes that occur early in life can impact our health de-
cades later. Various studies suggest that pathologic changes in AD can be
reversed prior to the development of symptoms through epigenetic
modiﬁcations (Fig. 1). Developmental exposure to lead (Pb) upregulates
genes involved in AD late in life through mechanisms that involve DNA
methylation and histone acetylation (Wu et al., 2008a; Bihaqi et al.,
2011; Bihaqi & Zawia, 2012). Persistent bidirectional changes in DNA
methylation in response to earlier Pb exposure are reported with
hypermethylation resulting in a latent reduction in gene expression
(Alashwal et al., 2012; Dosunmu et al., 2012). Moreover, cognitive im-
pairment accompanies overexpression of Sp1, BACE1, APP and Aβ late
in life following early exposure to Pb and consequential epigenetic alter-
ations (Bihaqi et al., in press). Such environmentally-induced changes
on AD related intermediates could be reversed via epigenetic mecha-
nisms. Alternatively, active epigenetic changes are involved in memory
formation and could be targeted for AD therapy. Modulation of epige-
netic intermediates could be a means for the upregulation of genes
that promote learning and memory, or reversing epigenetic changes
that are responsible for the overexpression of genes involved in AD
pathology. As neurons have a very limited ability to regenerate, revers-
ing pathological changes through targeting epigenetic intermediates
seems to be a promising therapeutic approach.
Interestingly, epigenetic targets in AD are also implicated in the path-
ophysiology of schizophrenia and depression (Covington et al., 2009;
Gavin & Sharma, 2010). Depression is a common comorbidity in de-
mented patients (Holtzer et al., 2005; Alzheimer's Association, 2012).
Psychotic symptoms, especially at later stages of the disease, are also
frequent in AD (Ropacki & Jeste, 2005; Alzheimer's Association, 2012).
Besides AD, HDAC inhibitors have been explored for other disorders in-
cluding schizophrenia and depression. For example, the HDAC inhibitor
sodium butyrate shows antidepressant activity in mice (Schroeder et
al., 2007). Sodium butyrate also protects against phencyclidine induced
psychotic-like behavior in mice (Koseki et al., 2012). It would be inter-
esting to study the effects of HDAC inhibitors as epigenetic modiﬁers on
cognitive as well as depressed and psychotic symptoms in AD patients.
Epigenetic alterations reported in AD are summarized in Table 1. A
major challenge for AD management is early diagnosis. Currently, no
standard criteria are available for early or accurate detection of AD
through reference values of biomarkers from patient CSF and blood
samples or imaging results. Epigenetic changes in AD could offer a diag-
nostic tool for the disease especially that some changes occur long
before the molecular pathology of AD develops. If such changes are
identiﬁed and detected early, reversing them via epigenetic therapeutic
approaches would prevent the triggering of alterations in gene expres-
sion and transcriptional cascade associated with the neuropathology of
AD. Also establishing criteria for epigenetic changes in AD can help ad-
minister disease-modifying drugs, once they become available, early in
the disease process. The use of epigenetics will likely be evenmore cru-
cial as the ﬁeld moves towards early and pre-symptomatic case detec-
tion and earlier attempts at intervention (Sperling et al., 2011).
The side effects of epigenetic targeting should also be studied. Atten-
tion should be made for the consequences of epigenetic modiﬁcations
that are involved in multiple pathways and which might serve various
functions within different cells and organs. Identiﬁcation of more spe-
ciﬁc targets and agents could be a way for minimizing toxicity. It is im-
portant to realize that drugs with epigenetic effects are already present
on the market. Some drugs used for years like the antihypertensive
agent hydralazine and the antiepileptic drug valproate are found to in-
terfere with epigenetic pathways which explains their previously un-
known mechanisms of action or some of their adverse effects and
HDACs
DNMTs
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Methyl Donors
SAM
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Resveratrol
SRT2104
SRT2379
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W2, I2
HAT activators p300 inhibitorsC646, Curcumin
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Sirtuins
DNA
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M
Fig. 1. Epigenetic targets and therapeutic approaches for AD. DNA methylation and histone modiﬁcation mediators involved in AD and potential therapeutic interventions under
development reported in literature. Barrels = histones; (M) = methyl group; (Ac) = acetyl group. Abbreviations in the ﬁgure are as follows: DNMT, DNA methyltransferase;
HAT, histone acetyltransferase; HDAC, histone deacetylase; SIRT, sirtuin.
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epigenetic alterations are desired (Csoka & Szyf, 2009).
Our knowledge about epigenetics is still limited, some mechanisms
have been studied more thoroughly like histone acetylation and DNA
methylation, yet much remains to be revealed, especially when it
comes to AD, memory and cognitive functions. Epigenetics is more
upstream in AD pathology than the more common or conventional tar-
gets such as BACE, γ-secretase, Aβ and tau and thus could be beneﬁcial
especially in early stages of the disease to prevent further transcription
and accumulation of pathological intermediates. Screening for such
modiﬁcations and diagnosis of AD at an early stage remain a challenge.
Nevertheless, promoting epigenetic mechanisms that trigger memory
formation and inhibit pathological events could be a novel and effective
therapeutic approach for preventing or at least delaying the develop-
ment of dementia. Epigenetics offer potential for AD where epigenetic
changes are integrated in the disease pathology. While no disease-
modifying candidate is available, more research is needed for the re-
ﬁnement of epigenetic targets and identiﬁcation of speciﬁc agents
that can improve cognition and prevent or slow AD. Although knowl-
edge is still being gathered about this ﬁeld of study, there is evidenceTable 1
Some epigenetic changes in AD reported in literature.
Epigenetic Mark Change Reference
HDAC2 Increase Graff et al. (2012)
HDAC6 Increase Ding et al. (2008)
SIRT1 Decrease Julien et al. (2009)
DNMT1 Decrease Mastroeni et al. (2010)
MicroRNA-101 Decrease Hebert et al. (2008)
MicroRNA-107 Decrease early in AD Wang et al. (2008b)
BACE1-AS Upregulated Faghihi et al. (2008)
Methylation on APP gene Hypomethylation West et al. (1995)
Methylation on APP, PS1, tau No change Barrachina & Ferrer (2009)that epigenetics could provide multi-target therapeutic approaches for
AD.
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